Validity of the prodromal risk syndrome for first psychosis: Findings from the north american prodrome longitudinal study

Schizophrenia Bulletin

Volumn 35, Issue 5, 2009, Pages 894-908

  Woods, Scott W ^a   Addington, Jean ^b   Cadenhead, Kristin S ^c   Cannon, Tyrone D ^d   Cornblatt, Barbara A ^e   Heinssen, Robert ^f   Perkins, Diana O ^g   Seidman, Larry J ^h   Tsuang, Ming T ^c,h   Walker, Elaine F ⁱ   McGlashan, Thomas H ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CALGARY   (Canada)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e ZUCKER HILLSIDE HOSPITAL   (United States)

^f NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

^g UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^h HARVARD MEDICAL SCHOOL   (United States)

ⁱ EMORY UNIVERSITY   (United States)

Author keywords

Prodrome; Psychosis; Risk syndrome; Schizophrenia; Schizotypy

Indexed keywords

ADULT; ARTICLE; COMORBIDITY; CONTROLLED STUDY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; FEMALE; FUNCTIONAL STATUS; HUMAN; MAJOR CLINICAL STUDY; MALE; PERSONALITY DISORDER; PRIORITY JOURNAL; PRODROMAL SYNDROME; PSYCHOSIS; RISK FACTOR; VALIDITY;

ADOLESCENT; COMORBIDITY; DISABILITY EVALUATION; DISEASE PROGRESSION; EARLY DIAGNOSIS; FEMALE; HUMANS; LONGITUDINAL STUDIES; MALE; PATIENT ACCEPTANCE OF HEALTH CARE; PSYCHIATRIC STATUS RATING SCALES; PSYCHOMETRICS; PSYCHOTIC DISORDERS; REPRODUCIBILITY OF RESULTS; RISK ASSESSMENT; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SCHIZOTYPAL PERSONALITY DISORDER; SOCIAL ADJUSTMENT; UNITED STATES; YOUNG ADULT;

EID: 69249151641     PISSN: 05867614     EISSN: 17451701     Source Type: Journal    
DOI: 10.1093/schbul/sbp027     Document Type: Article

References (98)

1. Gennaro AR, Gould GM. Blakiston's Gould Medical Dictionary. 4th ed. New York, NY: McGraw-Hill Book Company; 1979.
2. Bleuler E. Dementia Praecox or the Group of the Schizophrenias. New York, NY: International Universities Press; 1911.
3. Yung AR, McGorry PD, McFarlane CA, et al. Monitoring and care of young people at incipient risk of psychosis. Schizophr Bull. 1996;22:283-303.
4. Miller TJ, McGlashan TH, Rosen JL, et al. Prospective diagnosis of the initial prodrome for schizophrenia based on the Structured Interview for Prodromal Syndromes: preliminary evidence of interrater reliability and predictive validity. Am J Psychiatry. 2002;159:863-865.
5. Miller TJ, McGlashan TH, Rosen JL, et al. Prodromal assessment with the structured interview for prodromal syndromes and the Scale of Prodromal Symptoms: predictive validity, interrater reliability, and training to reliability. Schizophr Bull. 2003;29:703-715.
6. Miller TJ, Zipursky RB, Perkins D, et al. The PRIME North America randomized double-blind clinical trial of olanzapine versus placebo in patients at risk of being prodromally symptomatic for psychosis. II. Baseline characteristics of the "prodromal" sample. Schizophr Res. 2003;61:19-30.
7. Cornblatt BA, Lencz T, Smith CW, et al. The schizophrenia prodrome revisited: a neurodevelopmental perspective. Schizophr Bull. 2003;29:633-651.
8. Yung AR, Phillips LJ, Yuen HP, McGorry PD. Risk factors for psychosis in an ultra high-risk group: psychopathology and clinical features. Schizophr Res. 2004;67:131-142.
9. Morrison AP, French P, Walford L, et al. Cognitive therapy for the prevention of psychosis in people at ultra-high risk. Randomized controlled trial. Br J Psychiatry. 2004;184: 291-297.
10. Mason O, Startup M, Halpin S, et al. Risk factors for transition to first episode psychosis among individuals with 'at-risk mental states'. Schizophr Res. 2004;71:227-237.
11. Lam M, Hung SF, Chen EY. Transition to psychosis in Chinese high risk population. Schizophr Res. 2004;70:21.
12. Yung AR, Yuen HP, McGorry PD, et al. Mapping the onset of psychosis: the Comprehensive Assessment of At-Risk Mental States. Aust N Z J Psychiatry. 2005;39:964-971.
13. Broome MR, Woolley JB, Johns LC, et al. Outreach and support in south London (OASIS): implementation of a clinical service for prodromal psychosis and the at risk mental state. Eur Psychiatry. 2005;20:372-378.
14. Meyer SE, Bearden CE, Lux SR, et al. The psychosis prodrome in adolescent patients viewed through the lens of DSM-IV. J Child Adolesc Psychopharmacol. 2005;15:434-451.
15. Seeber K, Cadenhead KS. How does studying schizotypal personality disorder inform us about the prodrome for schizophrenia? Curr Psychiatry Rep. 2005;7:41-50.
16. Svirskis T, Korkeila J, Heinimaa M, et al. Axis-I disorders and vulnerability to psychosis. Schizophr Res. 2005;75: 439-446.
17. Rosen JL, Miller TJ,D'Andrea JT,McGlashan TH,Woods SW. Comorbid diagnoses in patients meeting criteria for the schizophrenia prodrome. Schizophr Res. 2006;85:124-131.
18. Simon AE, Dvorsky DN, Boesch J, et al. Defining subjects at risk for psychosis: a comparison of two approaches. Schizophr Res. 2006;81:83-90.
19. Haroun N, Dunn L, Haroun A, Cadenhead KS. Risk and protection in prodromal schizophrenia: ethical implications for clinical practice and future research. Schizophr Bull. 2006; 32:166-178.
20. Lemos S, Vallina O, Fernandez P, et al. Predictive validity of the Scale of Prodromal Symptoms (SOPS). Actas Esp Psiquiatr. 2006;34:216-223.
21. Yung AR, Stanford C, Cosgrave E, et al. Testing the Ultra High Risk (prodromal) criteria for the prediction of psychosis in a clinical sample of young people. Schizophr Res. 2006;84:57-66.
22. McGlashan TH, Zipursky RB, Perkins D, et al. Randomized, double-blind trial of olanzapine versus placebo in patients prodromally symptomatic for psychosis. Am J Psychiatry. 2006;163:790-799.
23. Riecher-Rossler A, Gschwandtner U, Aston J, et al. The Basel early-detection-of-psychosis (FEPSY)-study--design and preliminary results. Acta Psychiatr Scand. 2007;115:114-125.
24. Myles-Worsley M, Blailes F, Ord LM, et al. The Palau Early Psychosis Study: distribution of cases by level of genetic risk. Am J Med Genet B Neuropsychiatr Genet. 2007;144B:5-9.
25. Yung AR, Yuen HP, Berger G, et al. Declining transition rate in ultra high risk (prodromal) services: dilution or reduction of risk? Schizophr Bull. 2007;33:673-681.
26. Yung AR, Nelson B, Stanford C, et al. Validation of "prodromal" criteria to detect individuals at ultra high risk of psychosis: 2 year follow-up. Schizophr Res. 2008;105:10-17.
27. Olsen KA, Rosenbaum B. Prospective investigations of the prodromal state of schizophrenia: review of studies. Acta Psychiatr Scand. 2006;113:247-272.
28. Seidman LJ, Giuliano AJ, Smith CW, et al. Neuropsychological functioning in adolescents and young adults at genetic risk for schizophrenia and affective psychoses: results from the Harvard and Hillside Adolescent High Risk Studies. Schizophr Bull. 2006;32:507-524.
29. Niemi LT, Suvisaari JM, Tuulio-Henriksson A, Lonnqvist JK. Childhood developmental abnormalities in schizophrenia: evidence from high-risk studies. Schizophr Res. 2003;60: 239-258.
30. Addington J, Cadenhead KS, Cannon TD, et al. North American Prodrome Longitudinal Study: a collaborative multisite approach to prodromal schizophrenia research. Schizophr Bull. 2007;33:665-672.
31. Lencz T, Smith CW, Auther AM, Correll CU, Cornblatt BA. The assessment of "prodromal schizophrenia": unresolved issues and future directions. Schizophr Bull. 2003;29:717-728.
32. Robins E, Guze SB. Establishment of diagnostic validity in psychiatric illness: its application to schizophrenia. Am J Psychiatry. 1970;126:983-987.
33. Lencz T, Smith CW, Auther A, Correll CU, Cornblatt B. Nonspecific and attenuated negative symptoms in patients at clinical high-risk for schizophrenia. Schizophr Res. 2004; 68:37-48.
34. Hawkins KA, McGlashan TH, Quinlan D, et al. Factorial structure of the Scale of Prodromal Symptoms. Schizophr Res. 2004;68:339-347.
35. Keefe RSE, Perkins DO, Gu H, et al. A longitudinal study of neurocognitive function in individuals at-risk for psychosis. Schizophr Res. 2006;88:26-35.
36. Bearden CE, Soares JC, Klunder AD, et al. Three-dimensional mapping of hippocampal anatomy in adolescents with bipolar disorder [see comment]. J Am Acad Child Adolesc Psychiatry. 2008;47:515-525.
37. Eastvold AD, Heaton RK, Cadenhead KS. Neurocognitive deficits in the (putative) prodrome and first episode of psychosis. Schizophr Res. 2007;93:266-277.
38. Mittal VA, Dhruv S, Tessner KD, Walder DJ, Walker EF. The relations among putative biorisk markers in schizotypal adolescents: minor physical anomalies, movement abnormalities, and salivary cortisol. Biol Psychiatry. 2007;61:1179-1186.
39. Hall RC. Global assessment of functioning. A modified scale [see comments]. Psychosomatics. 1995;36:267-275.
40. Cannon-Spoor HE, Potkin SG, Wyatt RJ. Measurement of premorbid adjustment in chronic schizophrenia. Schizophr Bull. 1982;8:470-484.
41. Brill N, Reichenberg A, Weiser M, Rabinowitz J. Validity of the premorbid adjustment scale. Schizophr Bull. 2008;34: 981-983.
42. Cornblatt BA, Auther AM, Niendam T, et al. Preliminary findings for two new measures of social and role functioning in the prodromal phase of schizophrenia. Schizophr Bull. 2007;33:688-702.
43. First MB, Spitzer RL, Gibbon M, Williams JBW. Structured Clinical Interview for DSM-IV Axis I Disorders, Patient Edition, January 1995 FINAL, (SCID-I/P Version 2.0). New York, NY: Biometrics Research Department, New York State Psychiatric Institute; 1995.
44. Kaufman J, Birmaher B, Brent D, et al. Schedule for Affective Disorders and Schizophrenia for School-Age Children-Present and Lifetime Version (K-SADS-PL): initial reliability and validity data. J Am Acad Child Adolesc Psychiatry. 1997; 36:980-988.
45. Andreasen NC, Flaum M, Arndt S. The Comprehensive Assessment of Symptoms and History (CASH). An instrument for assessing diagnosis and psychopathology. Arch Gen Psychiatry. 1992;49:615-623.
46. Drake RE, Mueser KT, McHugo GJ. Clinician rating scales: Alcohol Use Scale (AUS), Drug Use Scale (DUS), and Substance Abuse Treatment Scale (SATS). In: Sederer LI, Dickey B, eds. Outcomes Assessment in Clinical Practice. Baltimore, Md: Williams & Wilkins; 1996.
47. Zimmerman M, Coryell W. The reliability of personality disorder diagnoses in a non-patient sample. J Pers Disord. 1989;3:53-57.
48. ZanariniMC, Frankenburg FR,ChaunceyDL, Gunderson JG. The diagnostic interview for personality disorders: interrater and test-retest reliability. Compr Psychiatry. 1987;28: 467-480.
49. First MB, Spitzer RL, Gibbon M, Williams JBW. Structured Clinical Interview for DSM-IV Personality Disorders (SCIDII). Washington, DC: American Psychiatric Press; 1997.
50. Endicott J, Andreasen NC, Spitzer RL. Family History Research Diagnostic Criteria. New York, NY: Biometrics Research Department, New York State Psychiatric Institute; 1975.
51. Maxwell ME. The family interview for genetic studies: manual. In: Clinical Neurogenetics Branch IRP. ed: National Institute of Mental Health, Washington, DC. 1992.
52. Cannon TD, Cadenhead KS, Cornblatt B, et al. Prediction of psychosis in youth at high clinical risk: a multisite longitudinal study in North America. Arch Gen Psychiatry. 2008;65:28-37.
53. McGorry PD, McFarlane C, Patton GC, et al. The prevalence of prodromal features of schizophrenia in adolescence: a preliminary survey. Acta Psychiatr Scand. 1995;92:241-249.
54. Bedwell JS, Donnelly RS. Schizotypal personality disorder or prodromal symptoms of schizophrenia? Schizophr Res. 2005;80:263-269.
55. Asarnow JR. Childhood-onset schizotypal disorder: a followup study and comparison with childhood-onset schizophrenia. J Child Adolesc Psychopharmacol. 2005;15:395-402.
56. Nordentoft M, Thorup A, Petersen L, et al. Transition rates from schizotypal disorder to psychotic disorder for firstcontact patients included in the OPUS trial. A randomized clinical trial of integrated treatment and standard treatment. Schizophr Res. 2006;83:29-40.
57. Hafner H, Maurer K, Loffler W, Riecher-Rossler A. The influence of age and sex on the onset and early course of schizophrenia. Br J Psychiatry. 1993;162:80-86.
58. Klosterkotter J, Hellmich M, Steinmeyer EM, Schultze-Lutter F. Diagnosing schizophrenia in the initial prodromal phase. Arch Gen Psychiatry. 2001;58:158-164.
59. Addington J, Chaves A, Addington D. Diagnostic stability over one year in first-episode psychosis. Schizophr Res. 2006; 86:71-75.
60. Schimmelmann BG, Conus P, Edwards J, McGorry PD, Lambert M. Diagnostic stability 18 months after treatment initiation for first-episode psychosis. J Clin Psychiatry. 2005; 66:1239-1246.
61. Schwartz JE, Fennig S, Tanenberg-Karant M, et al. Congruence of diagnoses 2 years after a first-admission diagnosis of psychosis. Arch Gen Psychiatry. 2000;57:593-600.
62. Veen ND, Selten JP, Schols D, et al. Diagnostic stability in a Dutch psychosis incidence cohort. Br J Psychiatry. 2004;185:460-464.
63. Amin S, Singh SP, Brewin J, et al. Diagnostic stability of firstepisode psychosis. Comparison of ICD-10 and DSM-III-R systems. Br J Psychiatry. 1999;175:537-543.
64. Amini H, Alaghband-rad J, Omid A, et al. Diagnostic stability in patients with first-episode psychosis. Australas Psychiatry. 2005;13:388-392.
65. Haahr U, Friis S, Larsen TK, et al. First-episode psychosis: diagnostic stability over one and two years. Psychopathology. 2008;41:322-329.
66. Correll CU, Penzner JB, Lencz T, et al. Early identification and high-risk strategies for bipolar disorder. Bipolar Disord. 2007;9:324-338.
67. Kendler KS, McGuire M, Gruenberg AM, et al. The Roscommon Family Study. IV. Affective illness, anxiety disorders, and alcoholism in relatives. Arch Gen Psychiatry. 1993;50:952-960.
68. Kendler KS, Karkowski-Shuman L, Walsh D. The risk for psychiatric illness in siblings of schizophrenics: the impact of psychotic and non-psychotic affective illness and alcoholism in parents. Acta Psychiatr Scand. 1996;94:49-55.
69. Williams NM, O'Donovan MC, Owen MJ. Is the dysbindin gene (DTNBP1) a susceptibility gene for schizophrenia? Schizophr Bull. 2005;31:800-805.
70. Tosato S, Dazzan P, Collier D. Association between the neuregulin 1 gene and schizophrenia: a systematic review. Schizophr Bull. 2005;31:613-617.
71. Green EK, Raybould R, Macgregor S, et al. Operation of the schizophrenia susceptibility gene, neuregulin 1, across traditional diagnostic boundaries to increase risk for bipolar disorder. Arch Gen Psychiatry. 2005;62:642-648.
72. Raybould R, Green EK, MacGregor S, et al. Bipolar disorder and polymorphisms in the dysbindin gene (DTNBP1). Biol Psychiatry. 2005;57:696-701.
73. Perkins DO. Risk of mania in persons at heightened clinical risk for psychosis. Paper presented at: 161st Annual Meeting of the American Psychiatric Association; May 7, 2008. Washington, DC.
74. Kendler KS, Gallagher TJ, Abelson JM, Kessler RC. Lifetime prevalence, demographic risk factors, and diagnostic validity of nonaffective psychosis as assessed in a US community sample. The National Comorbidity Survey. Arch Gen Psychiatry. 1996;53:1022-1031.
75. Kessler RC, Birnbaum H, Demler O, et al. The prevalence and correlates of nonaffective psychosis in the National Comorbidity Survey Replication (NCS-R). Biol Psychiatry. 2005;58:668-676.
76. Judd LL. Mood disorders in schizophrenia: epidemiology and comorbidity. J Clin Psychiatr Monogr Ser. 1998;16:2-4.
77. Cassano GB, Pini S, Saettoni M, Rucci P, Dell'Osso L. Occurrence and clinical correlates of psychiatric comorbidity in patients with psychotic disorders. J Clin Psychiatry. 1998; 59:60-68.
78. Strakowski SM, Shelton RC, Kolbrener ML. The effects of race and comorbidity on clinical diagnosis in patients with psychosis. J Clin Psychiatry. 1993;54:96-102.
79. Strakowski SM, Tohen M, Stoll AL, et al. Comorbidity in psychosis at first hospitalization. Am J Psychiatry. 1993;150: 752-757.
80. Sim K, Chua TH, Chan YH, Mahendran R, Chong SA. Psychiatric comorbidity in first episode schizophrenia: a 2 year, longitudinal outcome study. J Psychiatr Res. 2006;40: 656-663.
81. Bottlender R, Strauss A, Moller HJ. Prevalence and background factors of depression in first admitted schizophrenic patients. Acta Psychiatr Scand. 2000;101:153-160.
82. Koreen AR, Siris SG, Chakos M, et al. Depression in firstepisode schizophrenia. Am J Psychiatry. 1993;150:1643-1648.
83. Eaton WW, Romanoski A, Anthony JC, Nestadt G. Screening for psychosis in the general population with a self-report interview. J Nerv Ment Dis. 1991;179:689-693.
84. Tien AY. Distributions of hallucinations in the population. Soc Psychiatry Psychiatr Epidemiol. 1991;26:287-292.
85. van Os J, Hanssen M, Bijl RV, Ravelli A. Strauss (1969) revisited: a psychosis continuum in the general population? Schizophr Res. 2000;45:11-20.
86. Yung AR, Buckby JA, Cotton SM, et al. Psychotic-like experiences in nonpsychotic help-seekers: associations with distress, depression, and disability. Schizophr Bull. 2006;32:352-359.
87. Rossler W, Riecher-Rossler A, Angst J, et al. Psychotic experiences in the general population: a twenty-year prospective community study. Schizophr Res. 2007;92:1-14.
88. van Os J, Linscott RJ, Myin-Germeys I, Delespaul P, Krabbendam L. A systematic review and meta-analysis of the psychosis continuum: evidence for a psychosis proneness-persistence-impairment model of psychotic disorder. Psychol Med. 2009;39:179-195.
89. Nelson B, Yung AR, Bechdolf A, McGorry PD. The phenomenological critique and self-disturbance: implications for ultra-high risk ("prodrome") research. Schizophr Bull. 2008;34:381-392.
90. Hanssen M, Bak M, Bijl R, Vollebergh W, van Os J. The incidence and outcome of subclinical psychotic experiences in the general population. Br J Clin Psychol. 2005;44:181-191.
91. Woods SW, Miller TJ, McGlashan TH. The "prodromal" patient: both symptomatic and at-risk. CNS Spectr. 2001;6: 223-232.
92. Rosenberg PB, Johnston D, Lyketsos CG. A clinical approach to mild cognitive impairment. Am J Psychiatry. 2006; 163:1884-1890.
93. Sastre-Garriga J, Tintore M, Rovira A, et al. Specificity of Barkhof criteria in predicting conversion to multiple sclerosis when applied to clinically isolated brainstem syndromes. Arch Neurol. 2004;61:222-224.
94. McGorry PD, Hickie IB, Yung AR, Pantelis C, Jackson HJ. Clinical staging of psychiatric disorders: a heuristic framework for choosing earlier, safer and more effective interventions. Aust N Z J Psychiatry. 2006;40:616-622.
95. Dutta R, Greene T, Addington J, et al. Biological, life course, and cross-cultural studies all point toward the value of dimensional and developmental ratings in the classification of psychosis. Schizophr Bull. 2007;33:868-876.
96. Regier DA. Time for a fresh start? Rethinking psychosis in DSM-V. Schizophr Bull. 2007;33:843-845.
97. Cornblatt BA, Lencz T, Kane JM. Treatment of the schizophrenia prodrome: is it presently ethical? Schizophr Res. 2001; 51:31-38.
98. Corcoran C, Malaspina D, Hercher L. Prodromal interventions for schizophrenia vulnerability: the risks of being "at risk". Schizophr Res. 2005;73:173-184.